Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 7:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 756 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: End-stage Renal Disease Clear all
Recruiting Not applicable Interventional

Moda-flx Hemodialysis System™ Under Professional Care Settings by Trained Individuals and At Home by Participants

NCT06613568
View directory record Official record
Conditions
End Stage Kidney Disease
Interventions
Moda-flx Hemodialysis System™
Device
Lead sponsor
Diality Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
5
States / cities
San Dimas, California • New Hyde Park, New York • Knoxville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 14, 2026, 7:47 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Pilot Trial of Twice-weekly Versus Thrice-weekly Hemodialysis in Patients With Incident End-stage Kidney Disease

NCT03740048
View directory record Official record
Conditions
End Stage Renal Failure on Dialysis
Interventions
Hemodialysis, Patiromer Oral Product
Other · Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 9, 2023 · Synced Oct 14, 2026, 7:47 PM EDT
Not listed Not applicable Interventional

Timing of Acute Palliative Care Consultation in Critically Ill Patients

NCT02858778
View directory record Official record
Conditions
Multiple Organ Failure, End Stage Cardiac Failure, End Stage Chronic Obstructive Airways Disease, Chronic Kidney Disease Stage 5, Hepatic Encephalopathy, Sepsis, Dementia, Multiple Sclerosis, Parkinson's Disease, In-Hospital Cardiac Arrest, Solid Organ Cancer
Interventions
Early order of palliative care consultation
Other
Lead sponsor
Wayne State University
Other
Eligibility
65 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2016
U.S. locations
2
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 8, 2016 · Synced Oct 14, 2026, 7:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Study of BMS-914143 in Participants With Normal Renal Function and Mild, Moderate, Severe and End-stage Renal Dysfunction

NCT01708889
View directory record Official record
Conditions
Chronic Hepatitis B Virus Infection, Chronic Hepatitis C Virus Infection
Interventions
BMS-914143 (Peginterferon Lambda-1a)
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 5, 2013 · Synced Oct 14, 2026, 7:47 PM EDT
Completed Not applicable Interventional Results available

Continuous Glucose Monitoring in Patients With End-Stage Kidney Disease and Burnt-Out Diabetes

NCT05741489
View directory record Official record
Conditions
End Stage Kidney Disease
Interventions
Continuous glucose monitoring (CGM)
Device
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
4
States / cities
Atlanta, Georgia • Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 5, 2024 · Synced Oct 14, 2026, 7:47 PM EDT
Completed Phase 1 Interventional

Pharmacokinetics and Safety Pilot Study of Single-Dose Oral and Intravenous CTAP101 in Stage 3 and 4 Chronic Kidney Disease Subjects

NCT00888069
View directory record Official record
Conditions
Chronic Kidney Disease, Secondary Hyperparathyroidism, Chronic Renal Insufficiency, Chronic Renal Failure
Interventions
CTAP101 Capsules, CTAP101 Injection
Drug
Lead sponsor
OPKO IP Holdings II, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
12
States / cities
Peoria, Arizona • Evergreen Park, Illinois • Springfield, Massachusetts + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2014 · Synced Oct 14, 2026, 7:47 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study to Investigate the Effect of Triferic Plus Heparin Infusion Compared to Heparin Alone on Coagulation Parameters in Hemodialysis Patients

NCT04042324
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Triferic, Heparin
Drug
Lead sponsor
Rockwell Medical Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Dec 2, 2020 · Synced Oct 14, 2026, 7:47 PM EDT
Terminated Not applicable Interventional Results available

Immunomodulatory Biomimetic Device to Treat Myocardial Stunning in End-stage Renal Disease Patients

NCT03539861
View directory record Official record
Conditions
End Stage Renal Disease, Acute Kidney Injury, Chronic Kidney Disease Stage 5
Interventions
Hemodialysis
Device
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 17, 2023 · Synced Oct 14, 2026, 7:47 PM EDT
Completed No phase listed Observational

Comparative Outcome Measures of Patients Receiving Acute Renal ThErapy Study

NCT04912024
View directory record Official record
Conditions
End Stage Kidney Disease, End Stage Renal Disease, Acute Kidney Injury
Interventions
Intermittent Renal Replacement Therapy using the Tablo Hemodialysis System, Intermittent Renal Replacement Therapy using Conventional Hemodialysis Systems
Device
Lead sponsor
Outset Medical
Industry
Eligibility
18 Years and older
Enrollment
458 participants
Timeline
2021 – 2022
U.S. locations
2
States / cities
Orlando, Florida • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Aug 12, 2022 · Synced Oct 14, 2026, 7:47 PM EDT
Completed No phase listed Observational

Assessing Patient-Reported Experience of Care for Home Dialysis (ASPIRED)

NCT04435873
View directory record Official record
Conditions
Home Dialysis, End Stage Renal Disease
Interventions
Survey using "Your Home Dialysis Care Experience" tool.
Other
Lead sponsor
Satellite Healthcare
Other
Eligibility
18 Years and older
Enrollment
513 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
32
States / cities
Daly City, California • Emeryville, California • Folsom, California + 25 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2021 · Synced Oct 14, 2026, 7:47 PM EDT
Completed No phase listed Observational

Evaluation of a Virtual Home Dialysis Mentoring Program (Home)

NCT04806126
View directory record Official record
Conditions
End Stage Renal Disease on Dialysis, Home Dialysis
Interventions
Not listed
Lead sponsor
Satellite Healthcare
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
San Jose, California
Source: ClinicalTrials.gov public record
Updated May 20, 2022 · Synced Oct 14, 2026, 7:47 PM EDT
Completed No phase listed Observational

T-Wave Alternans in Dialysis Patients

NCT00621426
View directory record Official record
Conditions
Sudden Cardiac Death, End Stage Renal Disease
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 12, 2015 · Synced Oct 14, 2026, 7:47 PM EDT
Terminated Not applicable Interventional

A Pilot Study To Evaluate The CreatiVasc Hemoaccess Valve System In Patients Requiring Arteriovenous Graft Placement

NCT01644526
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Hemoaccess Valve System
Device
Lead sponsor
Diaxamed LLC
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 5, 2018 · Synced Oct 14, 2026, 7:47 PM EDT
Completed Not applicable Interventional

Tele-palliative Care in Rural Dialysis Patients

NCT03744117
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Palliative care consultation
Other
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Oct 6, 2022 · Synced Oct 14, 2026, 7:47 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics and Safety of Golcadomide in Participants With Severe Renal Impairment and End-Stage Renal Disease Compared With Participants With Normal Renal Function

NCT07763418
View directory record Official record
Conditions
Kidney Failure, Chronic
Interventions
Golcadomide
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 84 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
3
States / cities
Chandler, Arizona • Miami Lakes, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 14, 2026, 7:47 PM EDT
Active, not recruiting Phase 2 Interventional

Combination of Novel Therapies for CKD Comorbid Depression

NCT04422652
View directory record Official record
Conditions
Chronic Kidney Diseases, Major Depressive Disorder, End Stage Kidney Disease (ESRD)
Interventions
Bupropion, Behavioral activation therapy, Placebo, Clinical Management
Drug · Behavioral · Other
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
4
States / cities
Stony Brook, New York • Dallas, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 14, 2026, 7:47 PM EDT
Completed Not applicable Interventional Results available

Reducing Arrhythmia in Dialysis by Adjusting the Rx Electrolytes/Ultrafiltration, Study A

NCT03519347
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Potassium Removal Maximization, Potassium Gradient Minimization, Alkalosis Avoidance, Acidosis avoidance, Point of Care Testing, Cardiac Monitor
Other · Diagnostic Test · Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 85 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 15, 2023 · Synced Oct 14, 2026, 7:47 PM EDT
Active, not recruiting Phase 1 Interventional

Immunological Tolerance in Patients With Mismatched Kidney Transplants

NCT05806749
View directory record Official record
Conditions
End Stage Kidney Disease, Immunological Tolerance, Kidney Transplant Failure and Rejection, Chronic Kidney Diseases
Interventions
Donor CD34+, CD3+. and belumosudil
Combination Product
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 26, 2025 · Synced Oct 14, 2026, 7:47 PM EDT
Withdrawn Not applicable Interventional

Improving Access to Renal Transplantation for Underserved Black Communities

NCT06707038
View directory record Official record
Conditions
Kidney Transplant, ESRD (End Stage Renal Disease)
Interventions
AATAP intervention
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 9, 2025 · Synced Oct 14, 2026, 7:47 PM EDT
Completed Phase 3 Interventional Results available

Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression (BENEFIT)

NCT00256750
View directory record Official record
Conditions
Kidney Transplantation, Chronic Kidney Failure
Interventions
Cyclosporine (CsA), Belatacept LI (less intensive), Belatacept MI (more intensive)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
738 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
34
States / cities
Birmingham, Alabama • Loma Linda, California • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2016 · Synced Oct 14, 2026, 7:47 PM EDT
Completed Not applicable Interventional

Optimizing Kidney Transplant Informed Consent

NCT01859884
View directory record Official record
Conditions
End-stage Kidney Disease
Interventions
Inform Me: web-based education tool
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
21 Years and older
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
Birmingham, Alabama • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 20, 2015 · Synced Oct 14, 2026, 7:47 PM EDT
Completed No phase listed Observational Results available

Study to Evaluate the Prospective Payment System

NCT01717989
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Not listed
Lead sponsor
Amgen
Industry
Eligibility
Not listed
Enrollment
2,248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
40
States / cities
Gulf Shores, Alabama • Siloam Springs, Arkansas • Springdale, Arkansas + 32 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2014 · Synced Oct 14, 2026, 7:47 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Use of Immune Globulin Plus Rituximab for Desensitization in Highly HLA Sensitized Patients Awaiting Deceased Donor Kidney Transplantation

NCT01178216
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Rituxan
Biological
Lead sponsor
Stanley Jordan, MD
Other
Eligibility
18 Years to 70 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 26, 2018 · Synced Oct 14, 2026, 7:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetics (PK) and Safety of a Single Intravenous (IV) Dose of MK-3866 in Participants With Impaired Renal Function and in Healthy Controls (MK-3866-005)

NCT03259087
View directory record Official record
Conditions
Renal Impairment
Interventions
MK-3866
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
2
States / cities
Hialeah, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Apr 19, 2019 · Synced Oct 14, 2026, 7:47 PM EDT